Cargando…
Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans
BACKGROUND: Paclitaxel (PTX) products currently approved by the Food and Drug Administration include Kolliphor EL-paclitaxel micelles (KoEL-paclitaxel, Taxol) and nanoparticle albumin-bound paclitaxel (nab-paclitaxel, Abraxane). Despite containing the same cytotoxic agent, different PTX formulations...
Autores principales: | Li, Ying Fei, Zhang, Chengyue, Zhou, Simon, He, Miao, Zhang, Huixia, Chen, Nianhang, Li, Feng, Luan, Xin, Pai, Manjunath, Yuan, Hebao, Sun, Duxin, Li, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235005/ https://www.ncbi.nlm.nih.gov/pubmed/30519122 http://dx.doi.org/10.2147/CPAA.S185449 |
Ejemplares similares
-
Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel
por: Chen, Nianhang, et al.
Publicado: (2014) -
Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety
por: Gao, Wei, et al.
Publicado: (2022) -
Engineering exosomes as refined biological nanoplatforms for drug delivery
por: Luan, Xin, et al.
Publicado: (2017) -
MEOX1 Promotes Tumor Progression and Predicts Poor Prognosis in Human Non-Small-Cell Lung Cancer
por: Sun, Lichao, et al.
Publicado: (2019) -
Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies
por: Li, Yan, et al.
Publicado: (2020)